Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Check out the new look and feel of Harvard Catalyst Profiles! Learn more on our About and Help pages.

Eugene Braunwald, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. D28PE011123 (KOMAROFF, ANTHONY L.) Jul 1, 1989 - Jun 30, 1999
    HRSA/BHP
    RESIDENCY TRAINING IN GIM AND/OR GP
    Role: Co-Principal Investigator
  2. R01HL042311 (BRAUNWALD, EUGENE) Apr 1, 1989 - Dec 31, 1994
    NIH/NHLBI
    THROMBOLYSIS IN MYOCARDIAL ISCHEMIA-CLINICAL APPLICATION
    Role: Principal Investigator
  3. R01HL042419 (BRAUNWALD, EUGENE) Apr 1, 1989 - May 31, 1992
    NIH/NHLBI
    THROMBOLYSIS IN MYOCARDIAL ISCHEMIA-CORE APPLICATION
    Role: Co-Principal Investigator
  4. S10RR004135 (BRAUNWALD, EUGENE) May 24, 1988 - May 23, 1989
    NIH/NCRR
    BIOPOLYMER FACILITY FOR BIOMEDICAL RESEARCH
    Role: Principal Investigator
  5. D28PE011114 (BRAUNWALD, EUGENE) Jul 1, 1986 - Jun 30, 1988
    HRSA/BHP
    RESIDENCY TRAINING IN GIM AND/OR GP
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12; 137(24):2662-2663. PMID: 29891625.
    View in: PubMed
  2. Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Jun 01; 3(6):473-480. PMID: 29710336.
    View in: PubMed
  3. Braunwald E, Casadei B. Petar M. Seferovic new HFA President. Eur Heart J. 2018 May 21; 39(20):1754-1755. PMID: 29788299.
    View in: PubMed
  4. Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 May 14; 11(9):856-864. PMID: 29747915.
    View in: PubMed
  5. Douketis JD, Murphy SA, Antman EM, Grip LT, Mercuri MF, Ruff CT, Weitz JI, Braunwald E, Giugliano RP. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2018 Jun; 118(6):1001-1008. PMID: 29723874.
    View in: PubMed
  6. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018 May; 11(5):e003998. PMID: 29748353.
    View in: PubMed